Ovarian epithelial tumors 1. “Plasmacytoid junctional tumors, micropapillary subtype/non-invasive low-grade plasmacytoid carcinoma” and “low-grade plasmacytoid carcinoma”: plasmacytoid junctional tumors are histomorphologically and biologically between benign and carcinoma. The common type of plasmacytoma is named as “atypical proliferative plasmacytoma”, while the micropapillary tumor is named as “non-invasive micropapillary”. The common type of plasma junction tumor is named “atypical proliferative plasmacytoma”, while micropapillary tumor is named “non-invasive micropapillary (low-grade) plasmacytoma”. Micropapillary structures are associated with higher clinical stage and more infiltrative implantation, but are not significantly associated with overall patient prognosis. The extra-ovarian dissemination can be divided into non-invasive and invasive implants, with only the latter suggesting a poor prognosis, and the WHO considers invasive implants to be morphologically and biologically equivalent to “low-grade plasmacytoma”. Microinfiltrates of intersecting plasmacytoma: At present, the degenerated nosocomial tumor is directly diagnosed as “low-grade plasmacytoma” if it is 5 mm in size. 2.Low-grade/high-grade serous carcinoma (LGSC/HGSC): LGSC and HGSC are tumors that occur along different molecular pathways, and the original three-level classification (high-, medium- and low-differentiated plasmacytoma) has been replaced by the current two-level classification (high-grade and low-grade plasmacytoma). The original three-level classification (high-, mid-, and low-differentiated plasmacytoma) has been replaced by the current two-level classification (high- and low-grade plasmacytoma). High-grade plasmacytoma differs from low-grade plasmacytoma in terms of morphology, molecular genesis, biological behavior, and clinical treatment options. Some high-grade plasmacytomas are associated with BRCA1/2 mutations; almost all high-grade plasmacytomas have TP53 mutations. The new secondary classification only takes into account the heterogeneity of tumor cells and the number of nuclear schizograms, not their histological structure, with the following criteria (Table 1): Table 1 M.D. Anderson Cancer Center’s grading criteria Item High-grade plasmacytoma Low-grade plasmacytoma Nuclear heterogeneity More than 3-fold difference in size More uniform and consistent, only mild to moderate heterogeneity (<3< difference in size) span="">fold) Nuclear schizograms 12/10HPF ≤12/10HPF, often 2-3/10HPF 3. Non-plasmacytotic junctional tumors: For non-plasmacytotic “junctional” tumors, there is insufficient evidence of extra-ovarian involvement or patient death. 4. seromucinous tumours: An additional category of seromucinous tumours, including benign (seromucinous cystadenomas, adenofibromas), junctional (seromucinous junctional tumours / atypical hyperplastic seromucinous tumours) and malignant (seromucinous carcinomas) tumours. It is defined as a tumor containing two or more cellular components (at least 10% of each), with junctional and carcinoma emphasizing the presence of plasmacytic and endocervical-type mucinous epithelium, which may be accompanied by endometrioid, clear cell, squamous cell, or migratory cell components. The endocervical type of mucinous junctional tumor in the previous version is the plasma mucinous junctional tumor in the new WHO version. 5.Migratory cell carcinoma is eliminated: most of them are high-grade plasmacytoma, and some of them are low-differentiated endometrioid carcinoma or other types of carcinoma. 1.Low- and high-grade intraepithelial lesions (LSIL and HSIL): The new classification changes the original three-level classification of vulvar, vaginal and cervical squamous epithelial lesions to a two-level classification, so that cytology and histology The same terminology is used. 2. adenocarcinoma in situ, AIS and high-grade cervical glandular intraepithelial neoplasia: the recommended terminology is “adenocarcinoma in situ” and “high-grade cervical intraepithelial neoplasia”. “The term “adenocarcinoma in situ, AIS and high-grade cervical glandular intraepithelial neoplasia” is recommended as a synonym. Endometrial epithelial neoplasia A secondary classification is used for endometrial lesions, namely hyperplasia without atypia and atypical hyperplasia/endometrioid intraepithelial neoplasia. neoplasia), replacing a 4-group classification that has been in place since 1994. The new classification considers EIN to be equivalent to atypical hyperplasia, and the two are similar in terms of morphologic diagnostic criteria, reproducibility, and risk of progression to endometrioid neoplasia, thus unifying the two nomenclature systems. The two-level classification can meet the clinical requirements, both in terms of patient management options and prognostic assessment. The current difficulty in pathologic diagnosis lies in determining the presence or absence of atypia, which remains subjective and poorly reproducible by the individual pathologist, pending more reliable molecular indicators. Atypical hyperplasia/EIN unclassified. The new classification and diagnostic terms, representing the current level of academic understanding of gynecologic diseases, are also relevant to clinical management options and patient prognosis. Pathologists should grasp the concepts in the new version of the classification as soon as possible and do a good job of communication with the clinic.